Exciva
Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease
€51MSeries B
Role not disclosedCF
Carma Fund
Activity from announced rounds
Activity in this selectionJan 31, 2026 · Jan 1, 2026
Carma Fund is the investment brand named in the Allogenetics and Exciva financing histories.
Recorded funding activity
Allogenetics develops an ex vivo gene-therapy approach that modifies donor organs before transplantation to reduce rejection. Exciva develops therapies for behavioral symptoms associated with Alzheimer’s disease. The covered announcements use the unnumbered brand; they do not identify a particular fund vintage.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $59.8M 1 disclosed · full round size, not this investor’s share